Results 201 to 210 of about 14,917 (240)
Some of the next articles are maybe not open access.
Future Directions for the Use of Hypomethylating Agents
Seminars in Hematology, 2005Epigenetics refers to heritable changes in DNA and chromatin that impact gene expression without a change in DNA sequence. Two major steps involved in epigenetic regulation of gene expression include methylation of the promoter region of the gene and deacetylation of specific lysine residues on promoter-associated histones leading to changes in ...
Guillermo, Garcia-Manero, Steven D, Gore
openaire +2 more sources
Hypomethylating agents for patients with myelodysplastic syndrome
Cochrane Database of Systematic Reviews, 2011Reason for Withdrawal Authors have made no progress with this protocol in two years. New authors are being sought to take over this protocol. To view the published versions of this article, please click the 'Other versions' tab.
Kathrin Bauer +5 more
openaire +1 more source
Life after hypomethylating agents in myelodysplastic syndrome
Current Opinion in Hematology, 2015Hypomethylating agents, azacitidine and decitabine, are successfully used for the treatment of myelodysplastic syndromes (MDS). In spite of improvement in survival, MDS is still incurable without hematopoietic stem cell transplant, and in case of absence/loss of response to hypomethylating agents, outcome is poor.
openaire +3 more sources
DNA HYPOMETHYLATING AGENTS FOR CANCER THERAPY
2014The present invention relates to a method of treating and/or preventing cancer comprising administering a combination of an effective amount of a DNA hypomethylating agent and an effective amount of at least one immunomodulatory agent and/or optionally an effective amount of at least one targeted therapy agent.
MAIO MICHELE +2 more
openaire +2 more sources
Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes
Current Opinion in Hematology, 2018Purpose of review Hypomethylating agents (HMAs) are the standard of care for patients with myelodysplastic syndromes (MDS). Although these agents induce responses in up to 40% of patients, most patients ultimately experience loss of response.
Guillermo, Montalban-Bravo +2 more
openaire +2 more sources
Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes
Leukemia Research, 2012We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020).
Virginia M, Klimek +6 more
openaire +2 more sources
Hypomethylating agent based combinations in higher risk myelodysplastic syndrome
Leukemia & Lymphoma, 2019For over a decade the hypomethylating agents (HMA) azacitidine and decitabine have been the mainstay of therapy for myelodysplastic syndrome (MDS). There is a critical need to improve frontline therapy, given that only up to half of high-risk MDS patients will respond to HMA therapy, and responses are short-lived.
Namrata S. Chandhok +2 more
openaire +2 more sources
Making the most of hypomethylating agents in myelodysplastic syndromes
Current Opinion in Hematology, 2017Purpose of review Hypomethylating agents (HMA) are the preferred therapy for patients with higher risk myelodysplastic syndromes (MDS) and an alternative therapeutic strategy for older patients with acute myeloid leukemia. These agents have improved both survival and quality of life, but results overall remain poor. The purpose
Geetika, Bhatt, William, Blum
openaire +2 more sources
Blood
Introduction The Charlson Comorbidity Index (CCI) is a predictive multivariate co-morbidity index shown to predict mortality in patients with acute myeloid leukemia (AML). In our previous work, we demonstrated that a CCI of > 6 was independently predictive of prognosis when treated with a ...
Graeme F Murray +4 more
openaire +1 more source
Introduction The Charlson Comorbidity Index (CCI) is a predictive multivariate co-morbidity index shown to predict mortality in patients with acute myeloid leukemia (AML). In our previous work, we demonstrated that a CCI of > 6 was independently predictive of prognosis when treated with a ...
Graeme F Murray +4 more
openaire +1 more source
S-adenosyl-L-homocysteine: A non-cytotoxic hypomethylating agent
Experientia, 1994The cytotoxic effect caused by the hypomethylating agent S-adenosyl-L- homocysteine (SAH) was compared with that of two drugs commonly used to induce DNA hypomethylation, 5-azacytidine and 5-aza-2'-deoxycytidine. Two in vitro cytotoxicity tests, the tetrazolium MTT assay and the intracellular lactate dehydrogenase (LDH) activity test, suggest that SAH ...
S F, De Cabo +3 more
openaire +2 more sources